pegcetacoplan ophthalmic
Selected indexed studies
- Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. (Lancet, 2023) [PMID:37865470]
- Treatment of dry age-related macular degeneration: A review. (Clin Exp Ophthalmol, 2023) [PMID:37737509]
- Pegcetacoplan. (, 2006) [PMID:37094061]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Treatment of dry age-related macular degeneration: A review. (2023) pubmed
- Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. (2023) pubmed
- Pegcetacoplan. (2006) pubmed
- Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. (2020) pubmed
- Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE. (2025) pubmed
- Pegcetacoplan for Geographic Atrophy Over 30 Months: Data From OAKS, DERBY, and the GALE Long-Term Extension Study. (2025) pubmed
- Disease Activity and Therapeutic Response to Pegcetacoplan for Geographic Atrophy Identified by Deep Learning-Based Analysis of OCT. (2025) pubmed
- Efficacy of Intravitreal Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic Atrophy. (2025) pubmed
- Real-World Experience With Intravitreal Pegcetacoplan for the Treatment of Geographic Atrophy in Age-Related Macular Degeneration. (2026) pubmed
- Ocular Adverse Events Associated with Pegcetacoplan and Avacincaptad Pegol for Geographic Atrophy: A Population-Based Pharmacovigilance Study. (2025) pubmed